Log in

NASDAQ:INSYInsys Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.29
0.00 (0.00 %)
(As of 03/20/2020)
Add
Compare
Today's Range
$0.29
Now: $0.29
$0.29
50-Day Range
$0.23
MA: $23,687,640.18
$65,799,000.00
52-Week Range
$0.14
Now: $0.29
$11.65
VolumeN/A
Average Volume9.52 million shs
Market Capitalization$21.71 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Read More
Insys Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSY
Previous SymbolNASDAQ:NEOL
CUSIPN/A
Phone480-500-3127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.08 million
Book Value($0.58) per share

Profitability

Net Income$-124,510,000.00
Net Margins-346.61%

Miscellaneous

Employees226
Market Cap$21.71 million
Next Earnings DateN/A
OptionableOptionable

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) posted its earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company earned $7.63 million during the quarter, compared to analyst estimates of $14.95 million. Insys Therapeutics had a negative net margin of 346.61% and a negative return on equity of 1,430.37%. The firm's revenue was down 68.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share. View Insys Therapeutics' earnings history.

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were issued to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

Has Insys Therapeutics been receiving favorable news coverage?

Media stories about INSY stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insys Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutInsys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

What other stocks do shareholders of Insys Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insys Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Medivation (MDVN) and NVIDIA (NVDA).

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the following people:
  • Mr. Steven J. Meyer, Exec. Chairman (Age 62)
  • Mr. Saeed Motahari, CEO, Pres & Director (Age 53)
  • Mr. Andrew G. Long, Chief Financial Officer
  • Dr. Danny L. Tuck, Sr. VP of Quality Operations
  • Mr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $0.29.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $21.71 million and generates $82.08 million in revenue each year. The specialty pharmaceutical company earns $-124,510,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Insys Therapeutics employs 226 workers across the globe.

What is Insys Therapeutics' official website?

The official website for Insys Therapeutics is www.insysrx.com.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.